Arbutus Biopharma
ABUS
ABUS
50 hedge funds and large institutions have $133M invested in Arbutus Biopharma in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
1.01% more ownership
Funds ownership: 66.02% → 67.03% (+1%)
6% less funds holding
Funds holding: 53 → 50 (-3)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Holders
50
Holding in Top 10
2
Calls
$483K
Puts
$189K
Top Buyers
| 1 | +$13.5M | |
| 2 | +$478K | |
| 3 | +$308K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$170K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$142K |
Top Sellers
| 1 | -$5.2M | |
| 2 | -$3.63M | |
| 3 | -$1.44M | |
| 4 |
Goldman Sachs
New York
|
-$540K |
| 5 |
Jennison Associates
New York
|
-$455K |